Matt Trerotola has informed the Board of Directors at Enovis of his intention to retire from his position as Chief Executive Officer, effective upon his successor being appointed by the Board and assuming the position as CEO. The Board is actively working with an executive search firm to identify a growth-oriented medtech leader who shares our passion for continuous improvement and patient outcomes, to serve as the company’s next CEO.
Upon the appointment of his successor, Enovis and Mr. Trerotola will enter into a retirement and transition agreement whereby Mr. Trerotola will continue to serve as an employee and Executive Advisor to the company and his successor for one year.
Under Mr. Trerotola’s leadership, Enovis adopted an aggressive strategy to enter high-value market adjacencies, making it one of the most acquisitive companies in orthopedics. Being in the right segments with the right products catapulted the company’s reconstructive sales to the $1 billion market in 2024.
“Working with the exceptionally talented team at Enovis has been a great honor,” said Matt Trerotola. “I am deeply proud of all that we have accomplished over my tenure. Today, Enovis is a global company that is well positioned for continued growth thanks to our high-quality portfolio, focus on continuous improvement and exceptional team. Given the Company’s strong position, now is the right time to plan the transition to our next leader. I am excited to work closely with the Board to support a smooth handover and look forward to watching the business continue its industry leadership and above-market growth.”
Matt Trerotola has informed the Board of Directors at Enovis of his intention to retire from his position as Chief Executive Officer, effective upon his successor being appointed by the Board and assuming the position as CEO. The Board is actively working with an executive search firm to identify a growth-oriented medtech leader who shares our...
Matt Trerotola has informed the Board of Directors at Enovis of his intention to retire from his position as Chief Executive Officer, effective upon his successor being appointed by the Board and assuming the position as CEO. The Board is actively working with an executive search firm to identify a growth-oriented medtech leader who shares our passion for continuous improvement and patient outcomes, to serve as the company’s next CEO.
Upon the appointment of his successor, Enovis and Mr. Trerotola will enter into a retirement and transition agreement whereby Mr. Trerotola will continue to serve as an employee and Executive Advisor to the company and his successor for one year.
Under Mr. Trerotola’s leadership, Enovis adopted an aggressive strategy to enter high-value market adjacencies, making it one of the most acquisitive companies in orthopedics. Being in the right segments with the right products catapulted the company’s reconstructive sales to the $1 billion market in 2024.
“Working with the exceptionally talented team at Enovis has been a great honor,” said Matt Trerotola. “I am deeply proud of all that we have accomplished over my tenure. Today, Enovis is a global company that is well positioned for continued growth thanks to our high-quality portfolio, focus on continuous improvement and exceptional team. Given the Company’s strong position, now is the right time to plan the transition to our next leader. I am excited to work closely with the Board to support a smooth handover and look forward to watching the business continue its industry leadership and above-market growth.”
Copy to clipboard 
